J Clin Oncol 2010 Oct 10
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
Related Questions
Specifically, do you consider repeating maintenance therapy after second line therapy if a patient had already received 2 years of maintenance rituxim...
New comment by Medical Oncologist at Mayo Clinic College of Medicine and Science (Scottsdale) ( December 6, 2019)
Data for obinutuzumab comes from GADOLIN. In patients with rituximab-refractory disease, maintenance obinutuzumab was given after bendamustine/obinutuzumab and was associated ...